Navigation Links
IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery
Date:7/29/2010

MOUNTAIN VIEW, Calif., July 29 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the receipt of an Issue Notification from the U.S. Patent and Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of consumable medical devices already in the IRIDEX product line, collectively identified and sold as Adjustable and Intuitive EndoProbe® laser handpieces.

The Adjustable Laser Probe speeds up treatments by allowing continuous adjustment of the optical fiber over a wide range of angles for full coverage of the peripheral retina without requiring removal and reinsertion of the probe from the eye.

"We continue to focus on ways to increase the value of our consumable instrumentation line by offering novel and creative product solutions to our ophthalmic customers which in turn will help us grow our business," stated Theodore A. Boutacoff, President and CEO, "and to reconfirm our corporate position as a leader in our market."

"The issuance of this patent is valuable to IRIDEX because it helps us maintain the differentiation of our vitreoretinal product line from those of our competitors, and we plan to capitalize on the leverage afforded by this new patent by expanding this product line in the near future."

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's ability to increase the value of its consumable products, grow its business, differentiate its products and increase its product offerings in the near future.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2010 which was filed with the Securities and Exchange Commission and in our Quarterly Report on Form 10-Q for the fiscal quarter ended April 3, 2010. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX Announces First Commercial Shipment of New IQ 532(TM) Laser Systems
2. IRIDEX Announces First Quarter 2010 Conference Call and Release Date
3. IRIDEX Reports Fourth Quarter and Full Year 2009 Financial Results
4. IRIDEX Announces Fourth Quarter and Full Year 2009 Conference Call and Release Date
5. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
6. IRIDEX Introduces IQ 532 Dual Port Green Laser System at the American Academy of Ophthalmology
7. IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology
8. IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting
9. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
10. BSP Granted CE Mark for its HyperQ AD-100 Product Enabling Improved Diagnostic Performance of Stress ECG
11. Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... The new research portal will provide visitors ... company reports on UnitedHealth Group , as well ... in the healthcare industry. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... a fundamental transformation globally-a shift from a volume-based business ...
(Date:3/30/2017)... 30, 2017  Purcell Julie & Lefkowitz LLP, a class ... a potential breach of fiduciary duty claim involving the board ... ). If you are a shareholder of ... this investigation, free of charge, please visit us at: ... http://pjlfirm.com/synergy-pharmaceuticals-inc/ ...
(Date:3/29/2017)... Research and Markets has announced the addition ... their offering. ... The global gas chromatograph market to grow at a CAGR of ... Gas Chromatograph Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based dog ... Protect Law that assists dog owners in creating legally-enforceable pet trusts for their ... the natural next step to protect their new companion. Says Evan Dunbar, CEO of ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its ... Life" or "Wonder Spice", it has been used for thousands of years. , "The ... says Heshelow, author of " Turmeric: How to Use it For Your Wellness. Overcome ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... without a referral to new patients from Burnaby, BC. Patients in need of ... mouth reconstruction services, can see the esteemed team at Wall Centre Dental. Drs. ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... developing an ANSI-approved, consensus-based American National Standard for Good Manufacturing Practices (GMPs) ... first ANSI-approved GMP standard for dietary supplements this spring, is hiring an ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with wearing oral braces. "The rubber bands used in conjunction with my braces ... I decided to design a way to prevent this problem." The O.B.S. was ...
Breaking Medicine News(10 mins):